NASDAQ : ODTX
Odyssey Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 19.54 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 936.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 936.33M |
| Enterprise Value | 528.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 47.92M |
| Shares Outstanding | 47.92M |
| Shares Change (YoY) | +1,383.37% |
| Shares Change (QoQ) | +435.34% |
| Owned by Insiders (%) | 2.39% |
| Owned by Institutions (%) | 39.47% |
| Float | 23.66M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9,457.85 |
| Forward PS | n/a |
| PB Ratio | 2.22 |
| P/TBV Ratio | 2.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5,334.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.36 |
| Quick Ratio | 10.98 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,600.67 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -33.99% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $990 |
| Profits Per Employee | -$1.60M |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.04M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 21.79 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.94 |
| Average Volume (20 Days) | 243,868 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.28M |
| Short Previous Month | 3.11M |
| Short % of Shares Out | 6.85% |
| Short % of Float | 13.87% |
| Short Ratio (days to cover) | 8.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 99,000 |
| Gross Profit | -120.62M |
| Operating Income | -154.83M |
| Pretax Income | -161.07M |
| Net Income | -160.03M |
| EBITDA | -150.27M |
| EBIT | -154.83M |
| Loss Per Share | -$14.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 310.58M |
| Total Debt | 24.83M |
| Net Cash | 408.24M |
| Net Cash Per Share | $8.52 |
| Equity (Book Value) | 421.22M |
| Book Value Per Share | 8.80 |
| Working Capital | 293.17M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -132.13M |
| Capital Expenditures | -610,000 |
| Depreciation & Amortization | 4.56M |
| Net Borrowing | n/a |
| Free Cash Flow | -132.74M |
| FCF Per Share | -$2.77 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -156,392.93% |
| Pretax Margin | -162,695.96% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,383.37% |
| Shareholder Yield | -1,383.37% |
| Earnings Yield | -71.91% |
| FCF Yield | -14.18% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.33 |
| Price Target Difference | 80.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.7 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |